Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation

Bibliography

• Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011;106(9):1582-91
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349(14):1360-8
   PubMed Web of Science ®Google Scholar
• Longstreth G, Thompson W, Chey W, Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
   PubMed Web of Science ®Google Scholar
• Sun SX, Dibonaventura M, Purayidathil FW, Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci 2011;56(9):2688-95
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Ferrazzi S, Pare P, Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97(8):1986-93
   PubMed Web of Science ®Google Scholar
• Wald A, Sigurdsson L. Quality of life in children and adults with constipation. Best Pract Res Clin Gastroenterol 2011;25(1):19-27
   PubMed Web of Science ®Google Scholar
• Dennison C, Prasad M, Lloyd A, The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005;23(5):461-76
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009;7(5):502-8
   PubMed Web of Science ®Google Scholar
• Wald A, Scarpignato C, Mueller-Lissner S, A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008;28(7):917-30
   PubMed Web of Science ®Google Scholar
• Tack J. Current and future therapies for chronic constipation. Best Pract Res Clin Gastroenterol 2011;25(1):151-8
   PubMedGoogle Scholar
• American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005;100:S1-4
   PubMedGoogle Scholar
• Tack J, Müller-Lissner S, Stanghellini V, Diagnosis and treatment of chronic constipation–a European perspective. Neurogastroenterol Motil 2011;23(8):697-710
   PubMed Web of Science ®Google Scholar
• Gardner VY, Beckwith JV, Heyneman CA. Cisapride for the treatment of chronic idiopathic constipation. Ann Pharmacother 1995;29(11):1161-3
   PubMedGoogle Scholar
• Tack J, Müller-Lissner S, Bytzer P, A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54(12):1707-13
   PubMedGoogle Scholar
• Kamm MA, Müller-Lissner S, Talley NJ, Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100(2):362-72
   PubMedGoogle Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20(2):99-112
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35(7):745-67
   PubMed Web of Science ®Google Scholar
• Van De Velde VJ, Ausma J, Vandeplassche G. I.V. Kinetics and absolute oral bioavailability of prucalopride [abstract]. Gastroenterology 2010;138(5 Suppl 1):S-230
   Google Scholar
• Van De Velde VJ, Ausma J, Vandeplassche G. Food does not affect the oral bioavailability of prucalopride [abstract]. Gastroenterology 2009;136:A536
   Web of Science ®Google Scholar
• Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalorpide (Resolor®) in man [abstract no. P0891]. Proceedings of 16th United European Gastroenterology Week, Vienna, 2008. Gut 2008;57(Suppl II):A282
   Google Scholar
• Van De Velde VJ, Ausma J, Vandeplassche G. Comparative pharmacokinetics of prucalopride in healthy young and elderly subjects [abstract]. Gastroenterology 2010;138(5 Suppl 1):S-230
   Google Scholar
• Winter HS, Van De Velde VJ, Ausma J, Vandeplassche G. A single-dose pharmacokinetic trial of prucalopride solution in pediatric subjects with functional fecal retention [abstract]. Gastroenterology 2009;136:A510
   Google Scholar
• Galandiuk S, Beyens G, Ausma J, Vandeplassche L. Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor®) given subcutaneously in patients undergoing elective partial colectomies [abstract]. Gastroenterology 2008;134:A138
   Google Scholar
• Briejer MR, Bosmans JP, Van Daele P, The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423(1):71-83
   PubMed Web of Science ®Google Scholar
• Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokineticbenzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylatecyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989;340:403-10
   PubMed Web of Science ®Google Scholar
• Craig DA, Clarke DE. Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4 receptor activation. Br J Pharmacol 1991;102:563-4
   PubMed Web of Science ®Google Scholar
• LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum. Neurogastroenterol Motil 2004;16(3):355-64
   PubMed Web of Science ®Google Scholar
• Prins NH, Van Haselen JF, Lefebvre RA, Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999;127(6):1431-7
   PubMed Web of Science ®Google Scholar
• Prins NH, Shankley NP, Welsh NJ, An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000;129(8):1601-8
   PubMed Web of Science ®Google Scholar
• Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005;17(3):366-75
   PubMed Web of Science ®Google Scholar
• Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131(5):927-32
   PubMed Web of Science ®Google Scholar
• Cellek S, John AK, Thangiah R, 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006;18(9):853-61
   PubMed Web of Science ®Google Scholar
• Prins NH, van Der Grijn A, Lefebvre RA, 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132(8):1941-7
   PubMed Web of Science ®Google Scholar
• Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 2002;135(1):135-42
   PubMed Web of Science ®Google Scholar
• Qi HB, Luo JY, Liu X. Effect of enterokineticprucalopride on intestinal motility in fast rats. World J Gastroenterol 2003;9(9):2065-7
   PubMed Web of Science ®Google Scholar
• De Winter BY, Boeckxstaens GE, De Man JG, Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 1999;45(5):713-18
   PubMed Web of Science ®Google Scholar
• Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokineticprucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13(5):465-72
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42(4):511-16
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44(5):682-6
   PubMed Web of Science ®Google Scholar
• Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13(11):1493-7
   PubMed Web of Science ®Google Scholar
• De Schryver AM, Andriesse GI, Samsom M, The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002;16(3):603-12
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R, Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16(4):759-67
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, Baró I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther 2001;299(3):1007-12
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009;156(2):362-76
   PubMedGoogle Scholar
• Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. J Pharmacol Exp Ther 2005;313(1):146-53
   PubMedGoogle Scholar
• Mendzelevski B, Ausma J, Chanter DO, Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol 2012;73(2):203-9
   PubMed Web of Science ®Google Scholar
• Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67(1-2):82-9
   PubMed Web of Science ®Google Scholar
• Tack J, van Outryve M, Beyens G, Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58(3):357-65
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358(22):2344-54
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29(3):315-28
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010;22(9):991-8. e255
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21(12):1256-e117
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Farup C, Psychometric validation of a constipation symptomassessment questionnaire. Scand J Gastroenterol 1999;34(9):870-7
   PubMed Web of Science ®Google Scholar
• Marquis P, De La Loge C, Dubois D, Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005;40(5):540-51
   PubMed Web of Science ®Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):II43-7
   PubMedGoogle Scholar
• Winter HS, Ausma J, Vandeplassche L. An open label follow-up study of prucalopride solution in pediatric subjects with functional fecal retention [abstract]. Gastroenterology 2009;136(5 Suppl 1):A-129; 848
   Google Scholar
• Sloots CE, Rykx A, Cools M, Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55(10):2912-21
   PubMed Web of Science ®Google Scholar
• Krogh K, Jensen MB, Gandrup P, Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37:431-6
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002;97(1):194-7
   PubMedGoogle Scholar
• Emmanuel AV, Kamm MA, Roy AJ, Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012;35(1):48-55
   PubMed Web of Science ®Google Scholar
• Oustamanolakis P, Tack J. Prucalopride for chronic intestinal pseudo-obstruction: a novel therapy for a challenging condition. Aliment Pharmacol Ther 2012;35(3):398-9
   PubMedGoogle Scholar
• Gatandiuk S, Beyens G, Ausma J, Evaluation of the efficacy safety and tolerability of prucalopride (Resolor (R)) given subcutaneously in patients undergoing elective partial colectomies [abstract]. Gastroenterology 2008;134:A138
   Web of Science ®Google Scholar
• Camilleri M, Van Outryve MJ, Beyens G, Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32(9):1113-23
   PubMed Web of Science ®Google Scholar